Jubilant Pharmova’s wholly owned subsidiary -- Jubilant Draximage Inc., has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility at Montreal Canada in respect of the inspection conducted by the regulatory agency from June 6, 2022 to June 10, 2022. With the receipt of the EIR, the inspection stands successfully closed.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
